NCT00273429已完成4 期
Cosopt Versus Xalatan
Pharmaceutical Research Network4 个研究点 分布在 1 个国家开始时间: 2005年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 试验地点
- 4
研究概览
简要总结
To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
- •intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
- •ETDRS visual acuity must be 1.0 or better in both eyes
排除标准
- •any contraindications to study medications
- •any anticipated change in systemic hypertensive therapy during the trial
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Evaluation of dorzolamide/timolol fixed combination therapy for the patients who need more IOP reduction under PG analoguesprimary open angle glaucoma, ocular hypertensionJPRN-UMIN000004596Department of Ophthalmology, Kyoto Prefectural University of Medicine40
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analoguesprimary open angle glaucoma and ocular hypertensionJPRN-UMIN000006828Hospital, University of the Ryukyus40
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues and CAIGlaucomaJPRN-UMIN000006830Hospital, University of the Ryukyus20
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues and beta-blockerGlaucomaJPRN-UMIN000006829Hospital, University of the Ryukyus20
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues, beta-blocker and CAIJPRN-UMIN000006831Hospital, University of the Ryukyus20